首页> 外文OA文献 >Higher MICs (2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam

【2h】

Higher MICs (2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam

机译：较高的麦克风（> 2 mg / L）预测患有Ceftolozane / Tazobactam治疗的多药和广泛的耐药性铜绿假单胞菌患者患有较低呼吸道感染患者的30天死亡率

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Olga Rodríguez-Núñez; Leonor Periañez-Parraga; Antonio Oliver; Jose M Munita; Anna Boté; Oriol Gasch; Xavier Nuvials; Aurélien Dinh; Robert Shaw; Jose M Lomas; Vicente Torres; Juanjo Castón; Rafael Araos; Lilian M Abbo; Robert Rakita; Federico Pérez; Samuel L Aitken; Cesar A Arias; M Luisa Martín-Pena; Asun Colomar; M Belén Núñez; Josep Mensa; José Antonio Martínez; Alex Soriano;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15) [J] . Pfaller Michael A., Bassetti Matteo, Duncan Leonard R., The Journal of Antimicrobial Chemotherapy . 2017,第5期

机译：抗毒药肠杆菌和铜绿假西亚岛和铜绿假单胞菌的头孢噻唑胺活性导致欧洲尿路和肿瘤腹部感染：抗菌监测计划（2012-15）的报告
2. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013–2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program [J] . Dee Shortridge, Michael A Pfaller, Mariana Castanheira, Diagnostic microbiology and infectious disease . 2018,第2期

机译：Ceftolozane-Tazobactam的抗菌活性对肠杆菌痤疮和假单胞菌铜绿假单胞菌进行测试，并从美国医院（2013-2015）中分离的血流感染患者收集，作为评估头孢唑唑塔布·敏感性（协议）监测计划的方案的一部分
3. Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa. [J] . Patel N, McNutt LA, Lodise TP Antimicrobial agents and chemotherapy. . 2008,第8期

机译：铜绿假单胞菌引起的呼吸道感染患者先前使用抗生素的各种定义与哌拉西林-他唑巴坦耐药的关系。
4. Efficacy of antimicrobial impregnated urinary catheter in thwarting foreign body associated urinary tract infections caused by Pseudomonas aeruginosa [C] . Hina Saini, Sanjay Chhibber, Kusum Harjai World biomaterials congress . 2016

机译：抗菌浸渍导尿管对绿脓杆菌引起的异物相关尿路感染的抑制作用
5. Higher MICs (2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam [O] . Olga Rodríguez-Núñez, Leonor Periañez-Parraga, Antonio Oliver, 2019

机译：较高的MIC（ 2 mg / L）预测由头孢唑烷/他唑巴坦治疗的多药耐药和广泛耐药的铜绿假单胞菌引起的呼吸道感染较低的患者的30天死亡率
6. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15) [O] . Pfaller Michael A., Bassetti Matteo, Duncan Leonard R., 2017

机译：头孢洛赞/他唑巴坦对欧洲引起耐药菌和铜绿假单胞菌引起尿路和腹腔感染的耐药性：一项抗菌药物监测计划的报告（2012-15）

Higher MICs (2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam

著录项

引文网络

相似文献

相关主题

期刊订阅